Wednesday, July 8, 2026

biotech · Major Depressive Disorder · Schizophrenia · NBIX

NEUROCRINE BIOSCIENCES

NEUROCRINE BIOSCIENCES is a biotech organization headquartered in San Diego, USA. It trades on NYSE under ticker NBIX. Primary therapeutic focus areas include Major Depressive Disorder, Schizophrenia, Congenital Adrenal

6027 Edgewood Bend Ct, San Diego, California 92130, US HQ
1992 Founded
2,307 Employees
Public company Type
NBIX · NYSE Ticker
Company details
Status
Public
HQ
6027 Edgewood Bend Ct, San Diego, California 92130, US
Founded
1992
Employees
2,307
Programs
79
Drugs
28
Patents
111
Clinical program

NBI-1065845

Phase 3 · small molecule · Major Depressive Disorder

NBI-1065845 for Major Depressive Disorder is a Phase 3 program (small_molecule) at NEUROCRINE BIOSCIENCES INC with 5 ClinicalTrials.gov record(s).

← All NEUROCRINE BIOSCIENCES INC projects Phase 3 small molecule active

Internal code NBI-1065845-MDD3024

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
NEUROCRINE BIOSCIENCES INC
Phase
Phase 3
Modality
small_molecule
Indication
Major Depressive Disorder
Status
active
Trials
5